Class information for:
Level 1: EFAVIRENZ//NEVIRAPINE//CYP2B6

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
12516 900 35.8 79%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
29 3       HIV//VIROLOGY//HIV 1 108954
773 2             EFAVIRENZ//NEVIRAPINE//RALTEGRAVIR 12242
12516 1                   EFAVIRENZ//NEVIRAPINE//CYP2B6 900

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EFAVIRENZ authKW 2596183 24% 36% 215
2 NEVIRAPINE authKW 1790014 20% 29% 180
3 CYP2B6 authKW 918400 9% 35% 77
4 CYP2B6 POLYMORPHISM authKW 169633 1% 100% 5
5 EFAVIRENZ CONCENTRATIONS authKW 135707 0% 100% 4
6 BAMRASNARADURA INFECT DIS address 110806 2% 23% 14
7 CYP2B6 516G T authKW 101780 0% 100% 3
8 NEUROPSYCHIATRIC SIDE EFFECTS authKW 93944 1% 46% 6
9 UGANDANS authKW 90469 0% 67% 4
10 CNS SIDE EFFECTS authKW 84812 1% 50% 5

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Infectious Diseases 20781 45% 0% 406
2 Pharmacology & Pharmacy 5340 45% 0% 407
3 Virology 3097 14% 0% 130
4 Immunology 2343 25% 0% 229
5 Microbiology 1046 15% 0% 138
6 Toxicology 222 5% 0% 49
7 Medicine, General & Internal 65 6% 0% 51
8 Medical Laboratory Technology 55 2% 0% 14
9 Genetics & Heredity 49 5% 0% 41
10 Chemistry, Medicinal 36 3% 0% 24

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BAMRASNARADURA INFECT DIS 110806 2% 23% 14
2 AIDS UNIT INTERNAL MED 67853 0% 100% 2
3 HOP AMEDEO SAVOIA 67853 0% 100% 2
4 IPM STUDY 67853 0% 100% 2
5 PHARMACOGENET CANC GRP 45234 0% 67% 2
6 BAMRASNARADURA 43617 0% 43% 3
7 ESTUDOS DOENCAS CRON CEDOC 37001 1% 18% 6
8 5702 33927 0% 100% 1
9 ADULT INFECT DIS CARE CLIN IDCC 33927 0% 100% 1
10 AIDS EP USEA 33927 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 HIV MEDICINE 24325 3% 3% 28
2 PHARMACOGENETICS AND GENOMICS 15795 3% 2% 23
3 ANTIVIRAL THERAPY 15201 3% 2% 29
4 HIV CLINICAL TRIALS 12935 2% 3% 14
5 AIDS 12312 6% 1% 56
6 JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 10385 4% 1% 36
7 PHARMACOGENOMICS 8416 2% 1% 21
8 AIDS REVIEWS 5988 1% 3% 7
9 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 4520 5% 0% 41
10 AIDS RESEARCH AND THERAPY 4157 1% 2% 6

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 EFAVIRENZ 2596183 24% 36% 215 Search EFAVIRENZ Search EFAVIRENZ
2 NEVIRAPINE 1790014 20% 29% 180 Search NEVIRAPINE Search NEVIRAPINE
3 CYP2B6 918400 9% 35% 77 Search CYP2B6 Search CYP2B6
4 CYP2B6 POLYMORPHISM 169633 1% 100% 5 Search CYP2B6+POLYMORPHISM Search CYP2B6+POLYMORPHISM
5 EFAVIRENZ CONCENTRATIONS 135707 0% 100% 4 Search EFAVIRENZ+CONCENTRATIONS Search EFAVIRENZ+CONCENTRATIONS
6 CYP2B6 516G T 101780 0% 100% 3 Search CYP2B6+516G+T Search CYP2B6+516G+T
7 NEUROPSYCHIATRIC SIDE EFFECTS 93944 1% 46% 6 Search NEUROPSYCHIATRIC+SIDE+EFFECTS Search NEUROPSYCHIATRIC+SIDE+EFFECTS
8 UGANDANS 90469 0% 67% 4 Search UGANDANS Search UGANDANS
9 CNS SIDE EFFECTS 84812 1% 50% 5 Search CNS+SIDE+EFFECTS Search CNS+SIDE+EFFECTS
10 NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 71177 3% 9% 23 Search NON+NUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITORS Search NON+NUCLEOSIDE+REVERSE+TRANSCRIPTASE+INHIBITORS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 RUSSO, G , PAGANOTTI, GM , SOERIA-ATMADJA, S , HAVERKAMP, M , RAMOGOLA-MASIRE, D , VULLO, V , GUSTAFSSON, LL , (2016) PHARMACOGENETICS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN RESOURCE-LIMITED SETTINGS: INFLUENCE ON ANTIRETROVIRAL THERAPY RESPONSE AND CONCOMITANT ANTI-TUBERCULAR, ANTIMALARIAL AND CONTRACEPTIVE TREATMENTS.INFECTION GENETICS AND EVOLUTION. VOL. 37. ISSUE . P. 192 -207 90 73% 0
2 SWART, M , EVANS, J , SKELTON, M , CASTEL, S , WIESNER, L , SMITH, PJ , DANDARA, C , (2016) AN EXPANDED ANALYSIS OF PHARMACOGENETICS DETERMINANTS OF EFAVIRENZ RESPONSE THAT INCLUDES 3 '-UTR SINGLE NUCLEOTIDE POLYMORPHISMS AMONG BLACK SOUTH AFRICAN HIV/AIDS PATIENTS.FRONTIERS IN GENETICS. VOL. 6. ISSUE . P. - 62 84% 0
3 VO, TT , GUPTA, SV , (2016) ROLE OF CYTOCHROME P450 2B6 PHARMACOGENOMICS IN DETERMINING EFAVIRENZ-MEDIATED CENTRAL NERVOUS SYSTEM TOXICITY, TREATMENT OUTCOMES, AND DOSAGE ADJUSTMENTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION.PHARMACOTHERAPY. VOL. 36. ISSUE 12. P. 1245 -1254 50 94% 0
4 GENGIAH, TN , BOTHA, JH , YENDE-ZUMA, N , NAIDOO, K , KARIM, SSA , (2015) EFAVIRENZ DOSING: INFLUENCE OF DRUG METABOLIZING ENZYME POLYMORPHISMS AND CONCURRENT TUBERCULOSIS TREATMENT.ANTIVIRAL THERAPY. VOL. 20. ISSUE 3. P. 297 -306 45 96% 2
5 MCDONAGH, EM , LAU, JL , ALVARELLOS, ML , ALTMAN, RB , KLEIN, TE , (2015) PHARMGKB SUMMARY: EFAVIRENZ PATHWAY, PHARMACOKINETICS.PHARMACOGENETICS AND GENOMICS. VOL. 25. ISSUE 7. P. 363 -376 49 86% 1
6 DHORO, M , ZVADA, S , NGARA, B , NHACHI, C , KADZIRANGE, G , CHONZI, P , MASIMIREMBWA, C , (2015) CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE.BMC PHARMACOLOGY & TOXICOLOGY. VOL. 16. ISSUE . P. - 40 91% 9
7 APOSTOLOVA, N , FUNES, HA , BLAS-GARCIA, A , GALINDO, MJ , ALVAREZ, A , ESPLUGUES, JV , (2015) EFAVIRENZ AND THE CNS: WHAT WE ALREADY KNOW AND QUESTIONS THAT NEED TO BE ANSWERED.JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. VOL. 70. ISSUE 10. P. 2693 -2708 62 58% 9
8 NAIDOO, P , CHETTY, VV , CHETTY, M , (2014) IMPACT OF CYP POLYMORPHISMS, ETHNICITY AND SEX DIFFERENCES IN METABOLISM ON DOSING STRATEGIES: THE CASE OF EFAVIRENZ.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 70. ISSUE 4. P. 379-389 50 70% 10
9 SINXADI, PZ , LEGER, PD , MCILLERON, HM , SMITH, PJ , DAVE, JA , LEVITT, NS , MAARTENS, G , HAAS, DW , (2015) PHARMACOGENETICS OF PLASMA EFAVIRENZ EXPOSURE IN HIV-INFECTED ADULTS AND CHILDREN IN SOUTH AFRICA.BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 80. ISSUE 1. P. 146 -156 37 93% 4
10 ABDELHADY, AM , DESTA, Z , JIANG, F , YEO, CW , SHIN, JG , OVERHOLSER, BR , (2014) POPULATION PHARMACOGENETIC-BASED PHARMACOKINETIC MODELING OF EFAVIRENZ, 7-HYDROXY- AND 8-HYDROXYEFAVIRENZ.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 54. ISSUE 1. P. 87-96 37 95% 5

Classes with closest relation at Level 1


Rank Class id link
1 6181 ATAZANAVIR//RITONAVIR//LOPINAVIR
2 2716 ANTIRETROVIRAL THERAPY//ROYAL FREE HIV MED//CD4 CELL COUNT
3 7021 RALTEGRAVIR//DOLUTEGRAVIR//ETRAVIRINE
4 11702 I TECH SERV//LAMIVUDINE//EMTRICITABINE
5 20378 BUPROPION//HYDROXYBUPROPION//THREOHYDROBUPROPION
6 3304 CO INFECTION//HIV HCV COINFECTION//HIV
7 4819 PEDIATRIC HIV//EARLY INFANT DIAGNOSIS//EMPILWENI SERV UNIT
8 33978 AGROCHEMICAL INTERACTIONS//ATENOLOL METABOLIC ACTIONS//METOPROLOL METABOLIC ACTIONS
9 8662 PHARMACOGENOMICS//HLA B5701//PERSONALIZED MEDICINE
10 3220 TUBERCULOSIS//INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE//ISONIAZID PREVENTIVE THERAPY

Go to start page